Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Atomoxetine(click to collapse)
1/4 selected
Atomoxetine
Strattera
Selective Norepinephrine Reuptake Inhibitor
FDA-approved indications
- ADHD (adults; pediatric 6+)
Off-label uses
- Anxiety disorders with ADHD
- Binge eating disorder
Half-life5 hours
Decision GuideWhen to pick each / when to consider an alternative
Atomoxetine
Consider when
- ADHD with comorbid substance use disorder — non-scheduled; no abuse potential; preferred when stimulant diversion risk is high
- ADHD with comorbid anxiety — anxiolytic effect documented in trials; stimulants may worsen anxiety
- 24-hour ADHD coverage needed — continuous NRI effect without wearing-off; covers morning routine through sleep onset
- Tic disorder comorbidity — does not exacerbate tics; may improve ADHD symptoms without worsening Tourette's
- +1 more
Consider an alternative when
- Rapid ADHD symptom response needed — takes 4–6 weeks for full effect vs stimulant onset within hours
- Hepatic impairment — CYP2D6 substrate; dose reduction required in hepatic impairment; rare hepatotoxicity reported
- On potent CYP2D6 inhibitor (paroxetine, fluoxetine, bupropion) — levels increase 6–8× in PMs or with strong inhibitors
- Suicidal ideation risk in children/adolescents — boxed warning for increased SI in pediatric patients (0.4% vs 0%)
- +1 more
| Axis | Atomoxetine NRI |
|---|---|
| Boxed Warnings | |
Suicidality (boxed warning) | |
Mania / hypomania induction | |
Abuse / addiction liability | |
| CNS | |
Sedation / somnolence | |
Activation / insomnia | |
Seizure risk | |
Other neurologic effects | |
Dizziness | |
| Metabolic | |
Appetite suppression / anorexia | |
| Autonomic | |
Urinary retention / hesitancy | |
Sweating | |
Angle-closure glaucoma | |
| Cardiac | |
QTc prolongation | |
Serious CV / sudden death (ADHD labeled axis) | |
Blood pressure elevation | |
Heart rate / tachycardia | |
| GI | |
Nausea / GI (general) | |
| Hepatic | |
Liver enzymes / hepatotoxicity | |
| Sexual | |
Sexual dysfunction | |
| GU | |
Priapism | |
| Discontinuation | |
Withdrawal / discontinuation | |
| Interactions | |
MAOI co-administration contraindication | |
CYP interactions / DDI profile | |
| Safety | |
Overdose toxicity | |
| Pregnancy | |
Lactation / breastfeeding safety | |
| Drug-specific / distinctive axes | |
Pheochromocytoma (§4.4 CI) only in Atomoxetine | |